.boehringer New gTLD Application
Click to view Chinese translation articles.
-----------------------------------
New gTLD Application Submitted to ICANN by: Boehringer Ingelheim International GmbH
Application Downloaded On: 18 Mar 2015
String: boehringer
Application ID: 1-1967-32024
Applicant Information
- Full legal name
Boehringer Ingelheim International GmbH
- Address of the principal place of business
Binger Strasse 173 Ingelheim am Rhein, Rhineland-Palatinate - 55216 DE
- Phone number
+496132772316
- Fax number
+496132774566
- If applicable, website or URL
http://www.boehringer-ingelheim.com
Primary Contact
6(a). Name
Gretchen Olive
6(b). Title
Director of Policy & Industry Affairs
6(c). Address
6(d). Phone Number
013026365401
6(e). Fax Number
013026365454
6(f). Email Address
Secondary Contact
7(a). Name
Juergen Roemhild
7(b). Title
Head of CDept Intellectual Property Right and Unfair Competition (attorney)
7(c). Address
7(d). Phone Number
+496132772316
7(e). Fax Number
+496132774566
7(f). Email Address
Proof of Legal Establishment
8(a). Legal form of the Applicant
Limited Liability Company
8(b). State the specific national or other jurisdiction that defines the type of entity identified in 8(a).
German Law
8(c). Attach evidence of the applicant's establishment.
Attachments are not displayed on this form.
9(a). If applying company is publicly traded, provide the exchange and symbol.
9(b). If the applying entity is a subsidiary, provide the parent company.
9(c). If the applying entity is a joint venture, list all joint venture partners.
Applicant Background
11(a). Name(s) and position(s) of all directors
Name
Position
Allan Hillgrove Managing Director
Andreas Barner Managing Director
Hubertus von Baumbach Managing Director
Joachim Hasenmaier Managing Director
Wolfgang Baiker Managing Director
11(b). Name(s) and position(s) of all officers and partners
Name
Position
Adrian Carter Corporate Vice President
Alfred Rossel Corporate Vice President
Allan Hillgrove Corporate Vice President
Alois, Konrad Corporate VP
Andreas Winterfeldt Corporate Vice President
Andreas, Neumann, Dr. Corporate VP
Andrew, Owenson Corporate VP
Axel Wiest Corporate Vice President
Betina, Prestel Corporate VP
Christoph Gauger Corporate Vice President
Claudia Jesse Corporate Vice President
Claudia Sigg Corporate Vice President
David Wright Corporate Vice President
Dirk Schellenbeck Corporate Vice President
Dorothee Schwall-Rudolph Corporate Vice President
Dr. Andreas Felder Corporate VP
Dr. Christian Schilling Corporate Vice President
Dr. Christopher Corsico Corporate VP
Dr. Fridtjof Traulsen Corporate Vice President
Dr. Georg Fuchs Corporate Vice President
Dr. Gerd Benirschke Corporate VP
Dr. Isabelle Rengerink Corporate Vice President
Dr. Mark Hopley Corporate VP
Dr. Martin Schwarz Corporate Vice President
Dr. Oliver Freichel Corporate VP
Elke Simon Corporate Vice President
Engelbert Günster Corporate Vice President
Felix Gutsche Corporate VP
Frank Lennartz Corporate Vice President
Georg van Husen Corporate Vice President
Gerd Konzen Corporate Vice President
Gerd Schnorrenberg Corporate Vice President
Gerhard, Koller, Dr. Corporate VP
Gerrard, McKenna Corporate VP
Glyn Parkin Corporate Vice President
Guillermo Regueiro Corporate Vice President
Hans Michelberger Corporate Vice President
Hans-Joachim Geppert Corporate Vice President
Heidi, Hunter Corporate VP
Heinz Hammann Corporate Vice President
Heinz-Gerd Kläs Corporate Vice President
Herrad-Odilia Krenkel Corporate Vice President
Jan, Poth, Dr. Corporate VP
Jean Scheftsik de Szolnok Corporate Vice President
Joachim Wenzel Corporate Vice President
Jochen Gann Corporate Vice President
Jörg Barth Corporate Vice President
Jörg Hefer Corporate Vice President
Jörg Viernow Corporate Vice President
Jürgen Römhild Corporate Vice President
Karen, Roggemann Corporate VP
Klaus Dugi Corporate Vice President
Klaus Stern Corporate Vice President
Klaus Viel Corporate Vice President
Klaus Wilgenbus Corporate Vice President
Mark Hagmann Corporate VP
Mark John Lewis Corporate Vice President
Markus Weymann Corporate Vice President
Martin, Mauer Corporate VP
Maximilian Kammler Corporate Vice President
Michael Betke-Hornfeck Corporate Vice President
Michael Döll Corporate Vice President
Michael Klein Corporate Vice President
Michael Kompter Corporate Vice President
Michael Schmelmer Corporate Vice President
Michel Pairet Corporate Vice President
Monika Pieroth Corporate Vice President
Oliver Blattner Corporate Vice President
Paul Carter Corporate Vice President
Peter Overbeck Corporate Vice President
Raj, Kannan Corporate VP
Richard, Mole Corporate VP
Stefan Blaesius Corporate Vice President
Stefan Kilian Corporate Vice President
Stefan Rinn Corporate Vice President
Stephan Gotthardt Corporate Vice President
Stephan Lensky Corporate Vice President
Theo Nieuwenhuis Corporate Vice President
Thomas Mett Corporate Vice President
Thomas, Roth, Dr. Corporate VP
Thor Voigt Corporate Vice President
Thorsten, Pohl Corporate VP
Ulrich Drees Corporate Vice President
Ulrich Glas Corporate Vice President
Volker Bargon Corporate Vice President
Volker Mahlbacher Corporate Vice President
Wolfgang Graf Corporate Vice President
Wolfgang Rettig Corporate Vice President
11(c). Name(s) and position(s) of all shareholders holding at least 15% of shares
Name
Position
C.H.Boehringer Sohn AG & Co.KG Not Applicable
11(d). For an applying entity that does not have directors, officers, partners, or shareholders: Name(s) and position(s) of all individuals having legal or executive responsibility
Applied-for gTLD string
- Provide the applied-for gTLD string. If an IDN, provide the U-label.
boehringer
14A. If applying for an IDN, provide the A-label (beginning with "xn--").
14B. If an IDN, provide the meaning, or restatement of the string in English, that is, a description of the literal meaning of the string in the opinion of the applicant.
14C1. If an IDN, provide the language of the label (in English).
14C2. If an IDN, provide the language of the label (as referenced by ISO-639-1).
14D1. If an IDN, provide the script of the label (in English).
14D2. If an IDN, provide the script of the label (as referenced by ISO 15924).
14E. If an IDN, list all code points contained in the U-label according to Unicode form.
15A. If an IDN, upload IDN tables for the proposed registry. An IDN table must include:
the applied-for gTLD string relevant to the tables,
the script or language designator (as defined in BCP 47),
table version number,
effective date (DD Month YYYY), and
contact name, email address, and phone number.
Submission of IDN tables in a standards-based format is encouraged.
15B. Describe the process used for development of the IDN tables submitted, including consultations and sources used.
15C. List any variants to the applied-for gTLD string according to the relevant IDN tables.
- Describe the applicant's efforts to ensure that there are no known operational or rendering problems concerning the applied-for gTLD string. If such issues are known, describe steps that will be taken to mitigate these issues in software and other applications.
Applicant anticipates the introduction of this TLD without operational or rendering problems. Based on a decade of experience launching and operating new TLDs, Afilias, the back-end provider of registry services for this TLD, is confident the launch and operation of this TLD presents no known challenges. The rationale for this opinion includes:
- The string is not complex and is represented in standard ASCII characters and follows relevant technical, operational and policy standards;
- The string length is within lengths currently supported in the root and by ubiquitous Internet programs such as web browsers and mail applications;
- There are no new standards required for the introduction of this TLD;
- No onerous requirements are being made on registrars, registrants or Internet users, and;
- The existing secure, stable and reliable Afilias SRS, DNS, WHOIS and supporting systems and staff are amply provisioned and prepared to meet the needs of this TLD
- OPTIONAL.
Provide a representation of the label according to the International Phonetic Alphabet (http://www.langsci.ucl.ac.uk/ipa/).
18A. Describe the mission/purpose of your proposed gTLD.
CONFIDENTIAL
Mission & Purpose (Question 18) – Boehringer Ingelheim
18.1.1 Boehringer Ingelheim
Boehringer Ingelheim is a research-driven group of companies dedicated to researching and developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life.
Its businesses are Human Pharmaceuticals, Animal Health, Biopharmaceuticals and Chemicals. It focuses on innovative drugs and treatments that represent major therapeutic advances.
Excellence in innovation and technology guides its actions in all areas. The company’s products have long been highly successful in the treatment of respiratory, cardiovascular, central nervous system, urological and infectious disorders. In addition, the company has successfully advanced its research in, amongst others, thromboembolic, cardio-metabolic, and oncological diseases.
Boehringer Ingelheim has more than 42,000 employees in 145 affiliated companies, and operates global networks of research and development (R&D) facilities at seven sites and 20 production sites in 13 countries.
Corporate headquarters are in Ingelheim, the same German town where the family-owned company was founded in 1885.
The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped the company build on its strengths and make the most of its distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Today, real customer value can only be created by constantly developing new solutions and by building upon Boehringer Ingelheim’s core principles. .
18.1.2 Describe the mission⁄purpose of your proposed gTLD
The intended mission and purpose of the .boehringer gTLD is to serve as a trusted namespace for the benefit of Boehringer Ingelheim, its affiliated companies, Boehringer Ingelheim’s customers, the healthcare community and other Internet users.
Although ICANN has not specifically recognized a .BRAND gTLD specification in the current gTLD application round, it is widely anticipated in the brand-owner community that this will become a specialty subset of gTLDs. .boehringer is intended to become one of those .BRAND gTLDs, with the goal of protecting and enhancing Boehringer Ingelheim’s online presence and identity, expanding its marketing and promotion efforts, and potentially providing a secure channel for its products and services, among other uses.
Boehringer Ingelheim intends to initially use the .boehringer gTLD exclusively for corporate use. After the first few years of operation, and after analyzing the effect of new gTLDs on consumer behavior in the digital realm, Boehringer Ingelheim may evaluate whether opportunities exist to carry out the business strategy for the gTLD through expansion that continues the sustainable operations of the registry through registrations to parties other than Boehringer Ingelheim, such as licensees, alliance partners or customers.
Boehringer Ingelheim will operate the .boehringer gTLD in ways that are consistent with the business strategies of these or its other business segments as identified in its annual report and investor filings, see: http:⁄⁄www.boehringer-ingelheim.com⁄corporate_profile⁄annual_report.html.
18B. How do you expect that your proposed gTLD will benefit registrants, Internet users, and others?
18b. How do you expect that your proposed gTLD will benefit registrants, Internet users, and others?
The proposed .boehringer gTLD is a restricted gTLD that is intended to serve the purpose of enhancing and expanding Boehringer Ingelheim’s ability to:
-deliver products and healthcare-related services and service marketing⁄advertising;
-enable healthcare awareness and marketing campaign activation;
-facilitate interaction and communication with individuals and entities with whom Boehringer Ingelheim has a business relationship, in particular with healthcare professionals and patients;
-improve cooperation in the areas of research and development, medicine and business operations;
-simplify Internet user navigation to information about Boehringer Ingelheim products and services; and
-provide an online environment which instills trust and engenders confidence in Boehringer Ingelheim and its affiliates.
18b i. What is the goal of your proposed gTLD in terms of areas of specialty, service levels, or reputation?
Specialty – Boehringer Ingelheim is a global manufacturer and researcher of pharmaceuticals, and is one of the worldʹs 20 leading pharmaceutical companies. With the continued growth of the online channel in importance and significance, it is critical that Boehringer Ingelheim and its affiliated entities utilize all new online tools available to ensure that current and potential product⁄service customers can quickly find authorized, accurate information. Using the .boehringer gTLD will help Boehringer Ingelheim increase confidence of healthcare professionals and patients in the online content it makes available and provide a trusted destination for consumers to research product offerings.
Service levels – One of the key goals of the proposed .boehringer gTLD is to create a restricted, exclusively-controlled online environment for employees, healthcare professionals, patients and other customers (current and potential), suppliers, and other business partners that will increase customer confidence and trust in conducting business online. Through greater use of online tools by employees, healthcare professionals, patients and customers (current and potential), suppliers, and other business partners, Boehringer Ingelheim expects to further streamline business processes, reduce turn-around times, provide more personalized service, and improve overall customer⁄client service.
Reputation – Boehringer Ingelheim will operate the .boehringer gTLD in accordance with its leitbild (model), and its core principles, see: http:⁄⁄corporateresponsibility.boehringer-ingelheim.com⁄business_ethics.html.
Boehringer Ingelheim has been a successful, family-owned business for 125 years, and intends to remain such a business for the second century of its existence. Although it is impossible to predict the future precisely, the company is actively and creatively facing any changing tasks and challenges, building on its experiences and achievements. This provides the strength, direction, and confidence to shape its future.
In all its activities, Boehringer Ingelheim safeguards its employees, facilities and the environment from harmful influences, conserves natural resources, and promotes environmental awareness. Parallel to pursuing these goals, Boehringer Ingelheim seeks to foster economic and social well-being in the countries and communities in which it does business, in particular in the area of healthcare. In order to realize and achieve its goals, Boehringer Ingelheim must be financially successful, willing to make any necessary changes, and critically receptive to innovation, new ideas and developments. Maintaining and improving the performance of the company take precedence over maximizing earnings in the short term.
18b ii. What do you anticipate your proposed gTLD will add to the current space, in terms of competition, differentiation, or innovation?
Boehringer Ingelheim plans to operate the proposed .boehringer gTLD as a restricted, exclusively-controlled gTLD, and as such, domain names within the .boehringer gTLD will not be commercially offered for registration to the general public. Thus, Boehringer Ingelheim will have exclusive ownership over all second-level registrations within the .boehringer gTLD. As a result, Boehringer Ingelheim believes the proposed .boehringer gTLD will add to the current namespace in three (3) areas:
Competition – As technology advances, so too do customer expectations of companies online. They expect that companies will utilize the latest and greatest technology and online practices to improve the user experience, protect their information, and deliver quality service. Boehringer Ingelheim anticipates that the proposed .boehringer gTLD will enable it to communicate, interact, and protect data in ways and under conditions not possible under the existing namespace, thus enabling Boehringer Ingelheim and its affiliated entities to meet future customer expectations and competitive market demands.
Differentiation – While today, companies like Boehringer Ingelheim can register brand strings at the second-level (eg., boehringer.com), the proliferation of cybersquatting and typo squatting has placed a great burden on consumers to tread carefully online. In TLDs such as .COM, there is currently no guarantee that a domain name string that looks like a branded website is indeed an authorized website of the brand owner. Since the proposed .boehringer gTLD will be a restricted, exclusively-controlled online environment, where only authorized company web properties and e-mail will exist and operate online, the .boehringer gTLD will enable employees, customers, dealers, suppliers, other business partners, and Internet users to distinguish, on the face of the domain name alone, whether the site is an authorized company site because the gTLD.
Innovation - The proposed .boehringer gTLD, as a restricted, exclusively-controlled gTLD, will provide Boehringer Ingelheim with a new platform on which to build future innovation of its online presence, in particular in relation to its services and products.
18b iii. What goals does your proposed gTLD have in terms of user experience?
Boehringer Ingelheim operates in an industry that has been plagued by cybersquatting, typo squatting, phishing, pharming, and identity theft scams that take advantage of the personal and confidential data that is utilized in customer accounts. This malicious online conduct has shaken the trust and confidence of consumers to share information and transact business online. Thus, the proposed .boehringer gTLD has the following user experience goals:
-Foster trust and engender confidence in online interactions with Boehringer Ingelheim, its affiliates and licensees;
-Reduce the risk of Internet users being misled or believing and⁄or acting on erroneous information about Boehringer Ingelheim, its affiliates, and⁄or any of its products and services presented online by unauthorized 3rd parties; and
-Simplify online navigation to Boehringer Ingelheim activities, products, services, and affiliate information.
18b iv. Provide a complete description of the Boehringer Ingelheim’s intended registration policies in support of the goals listed above.
The proposed gTLD will be a restricted, exclusively-controlled gTLD where only Applicant, affiliated entities and authorized business partners will be permitted to register second-level domains for Applicant business purposes only for a term of one to ten years. Affiliated entities who are part of the same corporate organization as the Applicant who seek registrations for second-level names under the TLD will be required to present evidence in writing to accredited registrar(s) for the TLD demonstrating explicit authorization from an officer of the Applicant company to register second-level names within the TLD to protect against unauthorized registration within the TLD by unaffiliated third parties. Applicants and affiliated entities owned and⁄or controlled by the same corporate parent company will supply corporate contact and ownership information, not personal information, for each registration obtained under the TLD for display in the TLD WHOIS.
To the extent second-level domain names are ever registered to Applicant’s business partners and⁄or affiliates that are not owned by Applicant or its corporate parent company, registrants will be required to execute a registration agreement that incorporates all required ICANN consensus policies and other legal⁄policy requirements imposed on new gTLD applicants into the terms and conditions of the domain name registration agreement. Such registration may also be subject to additional terms and conditions under separate business partner and⁄or affiliate agreements with Applicant entity. Registrations by business partners or affiliates not owned by Applicant or its corporate parent company will require written, pre-approval by designated individual(s) at Applicant company, must provide corporate contact information, not personal information, for WHOIS purposes and must be made with Applicant’s registrar of choice. Registrants must not use the domain name in any way that may damage or diminish Applicants brand reputation, business relationships or other business interests. Failure to do any of the above will result in the immediate suspension of registrant’s registration agreement and⁄or all deletion of all domain names currently registered in the TLD.
18b vi. Will your proposed gTLD impose any measures for protecting the privacy or confidential information of registrants or users? If so, please describe any such measures.
The proposed .boehringer gTLD will be a restricted, exclusively-controlled gTLD where only Boehringer Ingelheim will authorize⁄issue registrations within the gTLD to itself and affiliated entities for business purposes. Corporate contact information will be clearly listed in the WHOIS record for each registration within the TLD.
As a leading pharmaceutical company, with extensive online operations, Boehringer Ingelheim has a vested interest in making sure all private and confidential information will be protected.
Boehringer Ingelheim will ensure that the operation of the .boehringer gTLD will be consistent with Boehringer Ingelheim’s commitment to data privacy (as evidenced by its current data privacy statement, http:⁄⁄bidocs.boehringeringelheim.com⁄BIWebAccess⁄ViewServlet.ser?docBase=renetnt&folderPath=⁄Privacy+Statements⁄BIPI+Online+Privacy+Policy.htm). Boehringer Ingelheim believes that the utilization of the proposed new gTLD could position its company to more fully meet new online challenges related to online privacy in the future.
18b viii. Describe whether and in what ways outreach and communications will help to achieve your projected benefits.
Boehringer Ingelheim anticipates that the .boehringer gTLD may play a significant role in the companyʹs future online strategy. The company will likely evaluate the recognition and adoption of new gTLDs, as well as the as the response from search engines in the marketplace, in order to create a successful outreach and communication strategy that coincides with its existing digital marketing initiatives. New strategies may involve:
-Informing the market of Boehringer Ingelheim’s ownership and planned use of the proposed .boehringer gTLD;
-Defining the expected benefits to healthcare professionals, clients, prospective clients, affiliates and Internet users at large.
18C. What operating rules will you adopt to eliminate or minimize social costs (e.g., time or financial resource costs, as well as various types of consumer vulnerabilities)? What other steps will you take to minimize negative consequences/costs imposed upon consumers?
18c. What operating rules will you adopt to eliminate or minimize social costs (e.g., time or financial resource costs, as well as various types of consumer vulnerabilities)? What other steps will you take to minimize negative consequences⁄costs imposed upon consumers?
Boehringer Ingelheim’s proposed initial limited use of the .boehringer gTLD will minimize social costs by eliminating the need for third-party brand owners to defensively register their trademark in the .boehringer gTLD, unlike with open registries. In addition, the .boehringer gTLD will provide consumers with a trusted source for the company’s content, goods, and services without the risk of fraud, misdirection, infringement, phishing, malware, and other scams that consumers are plagued with in .COM and other open gTLDs.
18c i. How will multiple applications for a particular domain name be resolved, for example, by auction or on a first-come⁄first serve basis?
There will not be multiple applications for a particular domain in the proposed .boehringer gTLD, because this will be a restricted, exclusively-controlled gTLD where only Boehringer Ingelheim will authorize⁄issue registrations within the gTLD to itself and affiliated entities for business purposes .
18c ii. Explain any cost benefits for registrants you intend to implement (e.g., advantageous pricing, introductory discounts, bulk registration discounts).
Boehringer Ingelheim does not envision any advantageous pricing, introductory discounts, or bulk registration discounts, because it will not be marketing or creating commercial initiatives for the sale of .boehringer domain names.
18c iii. Note that the Registry Agreement requires that registrars be offered the option to obtain initial domain name registrations for periods of one to ten years at the discretion of the registrar, but no greater than ten years. Additionally, the Registry Agreement requires advance written notice of price increases. Do you intend to make contractual commitments to registrants regarding the magnitude of price escalation? If so, please describe your plans.
The proposed .boehringer gTLD will be a self-funded, exclusively-controlled gTLD available only to Boehringer Ingelheim and affiliated entities. Thus, there will be no per domain name registration cost incurred by any party for this gTLD and thus, no price changes and⁄or escalations for which registrants will need to be notified.